EICHOR
● Active Not Recruiting
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Condition: Follicular Lymphoma (FL) · Sponsor: Genmab
About this study
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Around 1095 adult participants with previously untreated FL will be enrolled in approximately 250 sites across the world. Participants will receive R2 (intravenous \[IV\] infusion of rituximab (R) and oral capsules of lenalidomide) alone or in combination with subcutaneous injections of epcoritamab. Participants may also receive investigator's choice chemoimmunotherapy (CIT): IV infusion of obinutuzumab (G) and IV injections of cyclophosphamide, IV injections of doxorubicin, IV injections of vincristine, oral tablets of prednisone (CHOP) \[G-CHOP\]/ R-CHOP or G and IV infusion of bendamustine (Benda) \[G-Benda\]/R-Benda. The total treatment duration will be 120 weeks for all arms except A2, which is 24 weeks of treatment. There may be higher treatment burden for participants in this trial compared to their standard …
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (266)
| UCSF Fresno /ID# 264712 | Fresno, California, United States | — |
| Scripps Mercy Hospital /ID# 265393 | San Diego, California, United States | — |
| Sansum Clinic Research /ID# 261596 | Santa Barbara, California, United States | — |
| Rocky Mountain Cancer Centers - Boulder /ID# 261203 | Boulder, Colorado, United States | — |
| Christiana Care Health Service /ID# 261207 | Newark, Delaware, United States | — |
| Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 262445 | Jacksonville, Florida, United States | — |
| Advent Health /ID# 261578 | Orlando, Florida, United States | — |
| Orlando Health Cancer Institute /ID# 260983 | Orlando, Florida, United States | — |
| Moffitt Cancer Center /ID# 259487 | Tampa, Florida, United States | — |
| Beacon Cancer Care - Coeur d'Alene /ID# 260670 | Coeur d'Alene, Idaho, United States | — |
| Northwestern Medicine - Northwestern Memorial Hospital /ID# 259814 | Chicago, Illinois, United States | — |
| Cancer Care Specialists Of Central Illinois /ID# 272464 | Decatur, Illinois, United States | — |
+ 254 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06191744